Table 1 Sociodemographic and clinical characteristics of participants.
PETALE (cALL survivors) n = 248 | CHUM (control 1): age 19–40 years old, n = 47 | CARTaGENE (control 2): age 40–69 years old, n = 234 | |
|---|---|---|---|
Sex (all participants) | |||
Males (n, %) | 124; 50.0 | 14, 29.8 | 136, 56.9 |
Females (n, %) | 124; 50.0 | 33, 70.2 | 98, 41.0 |
Age at diagnosis, mean in years (s.d.) | 6.5 ( ± 4.5) | NA | NA |
Age at biomarker sampling, means in years (s.d.) | 22.3 ( ± 6.3) | 29.1 ( ± 5.3) | 54.5 ( ± 5.3) |
Post-treatment period, mean in years (s.d.) | 13.6 ( ± 5.3) | NA | NA |
Irradiation exposure | |||
Yes (n, %) | 149, 60.1 | NA | NA |
No (n, %) | 99, 39.9 | ||
Relapse risk group at diagnosis | |||
SR (n, %) | 111, 44.8 | ||
HR,cardioprotector (+) (n, %) | 69, 27.8 | NA | NA |
HR,cardioprotector (−) (n, %) | 60, 24.2 | ||
Metabolic syndrome | |||
All (n, %) | 22, 9.1 | NA | |
Males (n, %) | 12, 10.0 | ||
Females (n, %) | 10, 8.2 | ||
Abnormal TSH (Hypothyroidism) | |||
All (n, %) | 25, 10.3 | NA | NA |
Males (n, %) | 10, 8.3 | ||
Females (n, %) | 15, 12.3 | ||
Abnormal 6MWT | |||
All (n, %) | 92, 37.9 | NA | NA |
Males (n, %) | 45, 37.2 | ||
Females (n, %) | 47, 38.5 | ||
Abnormal CPET | |||
All (n, %) | 175, 82.2 | NA | NA |
Males (n, %) | 97, 45.5 | ||
Females (n, %) | 78, 36.6 | ||
